Inflammation and immunosuppression in severe acute pancreatitis

World Journal of Gastroenterology

Volumn 16, Issue 23, 2010, Pages 2867-2872

  Kylänpää, Marja Leena ^a   Repo, Heikki ^b   Puolakkainen, Pauli Antero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acute pancreatitis; Coagulation; Immunosuppression; Inflammatory response; Organ failure

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFLAMMATORY AGENT; CYTOKINE; DROTRECOGIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10 AGONIST; INTERLEUKIN 8 ANTIBODY; LEXIPAFANT; PLACEBO; PROTEIN C; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; AUTACOID;

ACUTE PANCREATITIS; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HOST; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; MEDIATOR; MONOCYTE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PROGNOSIS; RISK FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; ACUTE DISEASE; BIOSYNTHESIS; BLOOD; COMPLICATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PANCREATITIS; PATHOLOGY; SEPSIS;

ACUTE DISEASE; BLOOD COAGULATION; CYTOKINES; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INFLAMMATION MEDIATORS; MULTIPLE ORGAN FAILURE; PANCREATITIS; PROGNOSIS; SEPSIS;

EID: 77954260431     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i23.2867     Document Type: Article

References (83)

1. Eland IA, Sturkenboom MJ, Wilson JH, Stricker BH. Incidence and mortality of acute pancreatitis between 1985 and 1995. Scand J Gastroenterol 2000; 35: 1110-1116
2. Banks PA. Epidemiology, natural history, and predictors of disease outcome in acute and chronic pancreatitis. Gastrointest Endosc 2002; 56: S226-S230
3. Goldacre MJ, Roberts SE. Hospital admission for acute pancreatitis in an English population, 1963-98: database study of incidence and mortality. BMJ 2004; 328: 1466-1469
4. Andersson R, Andersson B, Haraldsen P, Drewsen G, Eckerwall G. Incidence, management and recurrence rate of acute pancreatitis. Scand J Gastroenterol 2004; 39: 891-894
5. Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA Jr. Increasing United States hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol 2007; 17: 491-497
6. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW. High early mortality rate from acute pancreatitis in Scotland, 1984-1995. Br J Surg 1999; 86: 1302-1305
7. Floyd A, Pedersen L, Nielsen GL, Thorladcius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981-2000. Scand J Gastroenterol 2002; 37: 1461-1465
8. de Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut 1995; 37: 121-126
9. Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, Banks PA. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997; 113: 899-903
10. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med 1994; 330: 1198-1210
11. Jaakkola M, Nordback I. Pancreatitis in Finland between 1970 and 1989. Gut 1993; 34: 1255-1260
12. Puolakkainen P, Kemppainen E, Leppäniemi A, Sainio V, Hietaranta A, Haapiainen R. Current principles of treatment in acute pancreatitis. Ann Chir Gynaecol 1998; 87: 200-203
13. Navaneethan U, Vege SS, Chari ST, Baron TH. Minimally invasive techniques in pancreatic necrosis. Pancreas 2009; 38: 867-875
14. De Waele JJ, Leppäniemi AK. Intra-abdominal hypertension in acute pancreatitis. World J Surg 2009; 33: 1128-1133
15. Jafri NS, Mahid SS, Idstein SR, Hornung CA, Galandiuk S. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis. Am J Surg 2009; 197: 806-813
16. Nowak A, Marek TA, Nowakowska-Duława E, Rybicka J, Kaczor R. Biliary pancreatitis needs endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy for cure. Endoscopy 1998; 30: A256-A259
17. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-134
18. Steer ML, Meldolesi J. Pathogenesis of acute pancreatitis. Annu Rev Med 1988; 39: 95-105
19. Otani T, Chepilko SM, Grendell JH, Gorelick FS. Codistribution of TAP and the granule membrane protein GRAMP-92 in rat caerulein-induced pancreatitis. Am J Physiol 1998; 275: G999-G1009
20. Singh VP, Saluja AK, Bhagat L, van Acker GJ, Song AM, Soltoff SP, Cantley LC, Steer ML. Phosphatidylinositol 3-kinase- dependent activation of trypsinogen modulates the severity of acute pancreatitis. J Clin Invest 2001; 108: 1387-1395
21. Warshaw AL. Damage prevention versus damage control in acute pancreatitis. Gastroenterology 1993; 104: 1216-1219
22. Steer ML. Frank Brooks memorial Lecture: The early intraacinar cell events which occur during acute pancreatitis. Pancreas 1998; 17: 31-37
23. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163-172
24. Montravers P, Chollet-Martin S, Marmuse JP, Gougerot- Pocidalo MA, Desmonts JM. Lymphatic release of cytokines during acute lung injury complicating severe pancreatitis. Am J Respir Crit Care Med 1995; 152: 1527-1533
25. Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-239
26. Osman MO, Jensen SL. Acute pancreatitis: the pathophysiological role of cytokines and integrins. New trends for treatment? Dig Surg 1999; 16: 347-362
27. Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001; 8: 187-194
28. Foitzik T, Eibl G, Hotz B, Hotz H, Kahrau S, Kasten C, Schneider P, Buhr HJ. Persistent multiple organ microcirculatory disorders in severe acute pancreatitis: experimental findings and clinical implications. Dig Dis Sci 2002; 47: 130-138
29. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125-1128
30. Mentula P, Kylänpää ML, Kemppainen E, Jansson SE, Sarna S, Puolakkainen P, Haapiainen R, Repo H. Plasma antiinflammatory cytokines and monocyte human leucocyte antigen-DR expression in patients with acute pancreatitis. Scand J Gastroenterol 2004; 39: 178-187
31. Beger HG, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986; 91: 433-438
32. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC Jr. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 1989; 77: 67-70
33. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-681
34. Tonegawa S. Antibody and T-cell receptors. JAMA 1988; 259: 1845-1847
35. Wolk K, Döcke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000; 96: 218-223
36. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002; 166: 1475-1482
37. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16: 457-499
38. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117: 1162-1172
39. García-Sabrido JL, Valdecantos E, Bastida E, Tellado JM. The anergic state as a predictor of pancreatic sepsis. Zentralbl Chir 1989; 114: 114-120
40. Kylänpää-Bäck ML, Takala A, Kemppainen E, Puolakkainen P, Kautiainen H, Jansson SE, Haapiainen R, Repo H. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scand J Gastroenterol 2001; 36: 1100-1107
41. Kylänpää-Bäck ML, Takala A, Kemppainen EA, Puolakkainen PA, Leppäniemi AK, Karonen SL, Orpana A, Haapiainen RK, Repo H. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. Crit Care Med 2001; 29: 63-69
42. Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. Gut 1999; 45: 895-899
43. Mentula P, Kylänpää ML, Kemppainen E, Jansson SE, Sarna S, Puolakkainen P, Haapiainen R, Repo H. Early prediction of organ failure by combined markers in patients with acute pancreatitis. Br J Surg 2005; 92: 68-75
44. Mentula P, Kylänpää-Bäck ML, Kemppainen E, Takala A, Jansson SE, Kautiainen H, Puolakkainen P, Haapiainen R, Repo H. Decreased HLA (human leucocyte antigen)-DR expression on peripheral blood monocytes predicts the development of organ failure in patients with acute pancreatitis. Clin Sci (Lond) 2003; 105: 409-417
45. Richter A, Nebe T, Wendl K, Schuster K, Klaebisch G, Quintel M, Lorenz D, Post S, Trede M. HLA-DR expression in acute pancreatitis. Eur J Surg 1999; 165: 947-951
46. Curley PJ, McMahon MJ, Lancaster F, Banks RE, Barclay GR, Shefta J, Boylston AW, Whicher JT. Reduction in circulating levels of CD4-positive lymphocytes in acute pancreatitis: relationship to endotoxin, interleukin 6 and disease severity. Br J Surg 1993; 80: 1312-1315
47. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128: 586-590
48. Lankisch PG, Pflichthofer D, Lehnick D. No strict correlation between necrosis and organ failure in acute pancreatitis. Pancreas 2000; 20: 319-322
49. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26 Suppl 1: S124-S128
50. Halonen KI, Pettilä V, Leppäniemi AK, Kemppainen EA, Puolakkainen PA, Haapiainen RK. Multiple organ dysfunction associated with severe acute pancreatitis. Crit Care Med 2002; 30: 1274-1279
51. Bollen TL, van Santvoort HC, Besselink MG, van Leeuwen MS, Horvath KD, Freeny PC, Gooszen HG. The Atlanta Classification of acute pancreatitis revisited. Br J Surg 2008; 95: 6-21
52. Lindström O, Jarva H, Meri S, Mentula P, Puolakkainen P, Kemppainen E, Haapiainen R, Repo H, Kylänpää L. Elevated levels of the complement regulator protein CD59 in severe acute pancreatitis. Scand J Gastroenterol 2008; 43: 350-355
53. Lindström O, Tukiainen E, Kylänpää L, Mentula P, Rouhiainen A, Puolakkainen P, Rauvala H, Repo H. Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis. Pancreas 2009; 38: e215-e220
54. Remes-Troche JM, Uscanga LF, Peláez-Luna M, Duarte-Rojo A, González-Balboa P, Teliz MA, Chan-Nunez C, Campuzano M, Robles-Díaz G. When should we be concerned about pancreatic necrosis? Analysis from a single institution in Mexico City. World J Surg 2006; 30: 2227-2233; discussion 2234-2235
55. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-69
56. Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas 2001; 22: 274-278
57. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002; 89: 298-302
58. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004; 53: 1340-1344
59. Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 1999; 27: 749-755
60. Guice KS, Oldham KT, Remick DG, Kunkel SL, Ward PA. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis. J Surg Res 1991; 51: 495-499
61. Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg 1994; 167: 214-218; discussion 218-219
62. Norman J, Franz M, Messina J, Riker A, Fabri PJ, Rosemurgy AS, Gower WR Jr. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995; 117: 648-655
63. Van Laethem JL, Marchant A, Delvaux A, Goldman M, Robberecht P, Velu T, Devière J. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995; 108: 1917-1922
64. Osman MO, Jacobsen NO, Kristensen JU, Deleuran B, Gesser B, Larsen CG, Jensen SL. IT 9302, a synthetic interleukin-10 agonist, diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery 1998; 124: 584-592
65. Osman MO, Kristensen JU, Jacobsen NO, Lausten SB, Deleuran B, Deleuran M, Gesser B, Matsushima K, Larsen CG, Jensen SL. A monoclonal anti-interleukin 8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental severe acute necrotising pancreatitis in rabbits. Gut 1998; 43: 232-239
66. Lundberg AH, Fukatsu K, Gaber L, Callicutt S, Kotb M, Wilcox H, Kudsk K, Gaber AO. Blocking pulmonary ICAM-1 expression ameliorates lung injury in established diet-induced pancreatitis. Ann Surg 2001; 233: 213-220
67. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414-1420
68. McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239-1243
69. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29: 646-651
70. Kylanpaa ML, Mentula P, Kemppainen E, Puolakkainen P, Aittomaki S, Silvennoinen O, Haapiainen R, Repo H. Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-gamma in vitro. Pancreas 2005; 31: 23-27
71. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592
72. Lasson A, Ohlsson K. Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb Res 1986; 41: 167-183
73. Salomone T, Tosi P, Palareti G, Tomassetti P, Migliori M, Guariento A, Saieva C, Raiti C, Romboli M, Gullo L. Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas 2003; 26: 111-116
74. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738
75. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPSinduced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-L202
76. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203
77. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49-S56
78. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719-3724
79. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
80. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341
81. Lindstrom O, Kylanpaa L, Mentula P, Puolakkainen P, Kemppainen E, Haapiainen R, Fernandez JA, Griffin JH, Repo H, Petaja J. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care 2006; 10: R16
82. Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernández-del Castillo C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006; 141: 670-676; discussion 676-677
83. Puolakkainen P, Repo H, Vainionpää S, Kylänpää L, Oiva J, Kemppainen E, Mustonen H. Defects in monocyte signaling in patients with acute pancreatitis. Pancreas 2009; 38: 1039